The global Chemiluminescence Immunoassay Market in terms of revenue was estimated to be worth $13.2 billion in 2023 and is poised to reach $19.0 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of infectious diseases and cancer and the growing geriatric population in chemiluminescence immunoassay.
On the other hand, the unfavourable reimbursement scenario and lack of skilled professionals may restrain the growth of this market to a certain extent.
Download a FREE Sample Report PDF of the Global Chemiluminescence Immunoassay Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131865271
The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A. (Italy). The market leadership of these players is owing to their comprehensive product portfolios and expansive global footprint. These dominant market players have several advantages, including strong research and development budgets, strong marketing and distribution networks, and well-established brand recognition.
Consumables segment accounted for the largest share of the chemiluminescence immunoassay industry in 2022, by product.
Based on product, the chemiluminescence immunoassay market is segmented as instruments and consumables. The consumables segment accounted for a significant share in the market in 2022. The recurring expenses associated with the frequent purchase of reagents & kits is a significant factor contributing to the market's growth. Besides, the availability of advanced consumables that offer better performance and reliability attributes to their widespread adoption resulting to the segment's growth.
Lab tests segment accounted for the largest share in the chemiluminescence immunoassay industry in 2022, by test type
On the basis of technology, the global chemiluminescence immunoassay market is categorized into Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay. In 2022, the CLEIA segment held the largest share in the market, by technology. The growth of the segment can be attributed to its high sensitivity and a broad dynamic range of applications ranging from clinical diagnostics, pharmaceutical research, environmental analysis, and food safety testing, among others.
Blood sample segment accounted for the largest share in the chemiluminescence immunoassay industry in 2022, by sample type.
Based on sample type, the chemiluminescence immunoassay market has been segmented into blood, saliva, urine, and other sample types. In 2022, the blood segment accounted for the largest share of the market. Blood enables the diagnosis of various indications that are not easily diagnosed using urine or saliva sample. Besides, with the rise in the number of blood donations and initiatives in support of blood screening, the segment is anticipated to also grow at the highest rate during the forecast period.
Direct Purchase of the Global Chemiluminescence Immunoassay Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=131865271
North America accounted for the largest share of the chemiluminescence immunoassay industry in 2022
The chemiluminescence immunoassay market is segmented into four major regions: North America, Europe, the Asia Pacific, and the Rest of the World. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the chemiluminescence immunoassay industry. With the presence of major players in the region, North America has witnessed various technological advancements in the field of chemiluminescence immunoassay. These companies have significant expertise, resources, and established sales networks, which contribute to the region’s market dominance. Examples of prominent chemiluminescence immunoassay companies in North America include Danaher Corporation (US) and Abbott Laboratories (US).
Comments